^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    p53MVA

    i
    Other names: MVA-p53, p53-MVA Vaccine, p53MVA, modified vaccinia ankara, MVAp53, Modified Vaccinia Virus Ankara Vaccine Expressing p53
    Associations

    News

    Trials
    Company:
    City of Hope, Tara I-O
    Drug class:
    p53 stimulant
    Related drugs:
    Associations

    News

    Trials
    1m
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    7ms
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    PD-L1 expression • TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    8ms
    Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Combination therapy
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability)
    |
    TP53 mutation • TP53 expression • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    11ms
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    PD-L1 expression • TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    over1year
    Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, City of Hope Medical Center | N=19 --> 11 | Trial completion date: Dec 2022 --> Dec 2023
    Enrollment change • Trial completion date • Combination therapy
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    TP53 mutation • TP53 expression • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    2years
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    PD-L1 expression • TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    over2years
    Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022
    Trial completion date • Combination therapy
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    TP53 mutation • TP53 expression • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    almost3years
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2022 --> Dec 2023 | Trial primary completion date: Jan 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    PD-L1 expression • TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    over3years
    Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2020 --> Dec 2021
    Clinical • Trial completion date • Combination therapy
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    TP53 mutation • TP53 expression • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    almost4years
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
    Clinical • Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    PD-L1 expression • TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    over4years
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
    Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    PD-L1 expression • TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA